Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial
Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Safety and immunogenicity were tested in patient...
Saved in:
| Published in | PloS one Vol. 9; no. 11; p. e112556 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
14.11.2014
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant.
Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-β.
Vacc-4x proliferative T cell responses increased only among the vaccinated (p ≤ 0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p < 0.001) and high regulation (r = 0.61, p = 0.010) at baseline.
Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation.
ClinicalTrials.gov NCT01473810. |
|---|---|
| AbstractList | Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Methods Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-[beta]. Results Vacc-4x proliferative T cell responses increased only among the vaccinated (p[less than or equal to]0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p<0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Conclusion Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation. Trial Registration ClinicalTrials.gov NCT01473810 Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant.Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-β.Vacc-4x proliferative T cell responses increased only among the vaccinated (p ≤ 0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p < 0.001) and high regulation (r = 0.61, p = 0.010) at baseline.Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation.ClinicalTrials.gov NCT01473810. BACKGROUNDVacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant.METHODSSafety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-β.RESULTSVacc-4x proliferative T cell responses increased only among the vaccinated (p ≤ 0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p < 0.001) and high regulation (r = 0.61, p = 0.010) at baseline.CONCLUSIONIntranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation.TRIAL REGISTRATIONClinicalTrials.gov NCT01473810. Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Methods Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-ß. Results Vacc-4x proliferative T cell responses increased only among the vaccinated (p=0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p<0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Conclusion Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation. Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-[beta]. Vacc-4x proliferative T cell responses increased only among the vaccinated (p[less than or equal to]0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p<0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation. Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-β. Vacc-4x proliferative T cell responses increased only among the vaccinated (p ≤ 0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p < 0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation. ClinicalTrials.gov NCT01473810. Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Methods Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-β. Results Vacc-4x proliferative T cell responses increased only among the vaccinated (p≤0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = −0.82, p<0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Conclusion Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation. Trial Registration ClinicalTrials.gov NCT01473810 Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Methods Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-β. Results Vacc-4x proliferative T cell responses increased only among the vaccinated (p≤0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = −0.82, p<0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Conclusion Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation. Trial Registration ClinicalTrials.gov NCT01473810 |
| Audience | Academic |
| Author | Kvale, Dag Haugen, Inger Lise Lind, Andreas Holm-Hansen, Carol Sørensen, Birger Sommerfelt, Maja Brekke, Kristin |
| AuthorAffiliation | 3 Bionor Pharma, Oslo, Norway University of Alabama, United States of America 4 University of Oslo, Oslo, Norway 2 Norwegian Institute of Public Health, Oslo, Norway 1 Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway |
| AuthorAffiliation_xml | – name: 4 University of Oslo, Oslo, Norway – name: 1 Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway – name: 3 Bionor Pharma, Oslo, Norway – name: University of Alabama, United States of America – name: 2 Norwegian Institute of Public Health, Oslo, Norway |
| Author_xml | – sequence: 1 givenname: Kristin surname: Brekke fullname: Brekke, Kristin – sequence: 2 givenname: Andreas surname: Lind fullname: Lind, Andreas – sequence: 3 givenname: Carol surname: Holm-Hansen fullname: Holm-Hansen, Carol – sequence: 4 givenname: Inger Lise surname: Haugen fullname: Haugen, Inger Lise – sequence: 5 givenname: Birger surname: Sørensen fullname: Sørensen, Birger – sequence: 6 givenname: Maja surname: Sommerfelt fullname: Sommerfelt, Maja – sequence: 7 givenname: Dag surname: Kvale fullname: Kvale, Dag |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25398137$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUk1v1DAQjVARbRf-AYJIXMohiz8SJ74gVRXQlSpxgV6tie1svUrsxU4qyo_htzKhu6WLKh8yGb83b2b8TrMjH7zNsteULCmv6YdNmKKHfrnF9JJQyqpKPMtOqOSsEIzwo0fxcXaa0oaQijdCvMiOWcVlg1VOst8rP0bwkKDPwQzOu4T_ows-D10O-XhjI2ztNDqdX66u81vQ2nmbn11jUJQ_3-fOm0nblJuQbGHs1npj_ZinuzTaAVngTT5MOswKbhgmJEebsOuEJOdRA_VNGNwva3IdsJ3Q9xiO0UH_MnveQZ_sq913kX3__OnbxWVx9fXL6uL8qtCC1mPRVmDbkhnKNGspr6CVkkFVdgbKqhEAVVNyA01dW1l3hmrZGg0CjAGjhSV8kb29r7vtQ1K71SZFZS0lFxIXuchW9wgTYKO20Q0Q71QAp_4mQlwriLil3iraCCJJUwKRpmSMtk3FayNqW7eaEdBY6-NObWoHa7Sd36A_KHp4492NWodbVTLOuGj-tasjvpfzyocIipKmYoghdEac7SRi-DHZNKrBJW37HrwNE04mWNPUsuYUoe_-gz49_w61BhzR-S5gZ3ouqs5LisJSkBpRyydQeMzsBXRq5zB_QCj3k4SUou0etkCJmn2-b0bNPlc7nyPtzeMNPpD2xuZ_AOyY_ko |
| CitedBy_id | crossref_primary_10_1007_s10989_021_10296_8 crossref_primary_10_2174_1573395514666180605092054 crossref_primary_10_1016_j_jim_2017_01_010 crossref_primary_10_1186_s12879_017_2316_x crossref_primary_10_1186_s12985_017_0698_4 crossref_primary_10_1016_j_vaccine_2023_05_011 crossref_primary_10_3390_pharmaceutics14101983 crossref_primary_10_1080_21645515_2018_1461296 crossref_primary_10_1016_j_bjid_2023_102774 crossref_primary_10_1371_journal_pone_0148984 crossref_primary_10_3389_fimmu_2023_1186478 crossref_primary_10_1080_14760584_2022_2059467 crossref_primary_10_1016_j_ijpharm_2019_118813 crossref_primary_10_1038_s41577_020_0274_9 crossref_primary_10_3390_ijms19113639 crossref_primary_10_1016_j_jvacx_2021_100105 crossref_primary_10_1080_14760584_2019_1692657 crossref_primary_10_1371_journal_pone_0153849 crossref_primary_10_3390_pharmaceutics14051073 crossref_primary_10_1016_j_jconrel_2020_11_009 |
| Cites_doi | 10.1016/j.immuni.2011.01.015 10.1371/journal.pone.0055438 10.1089/aid.2004.20.972 10.1038/nprot.2007.297 10.1016/S0140-6736(13)60104-X 10.1586/14760584.8.1.103 10.1016/0264-410X(92)90517-N 10.1002/cyto.a.20905 10.1097/00002030-200409240-00003 10.1016/j.vaccine.2014.03.061 10.1007/s11904-012-0118-8 10.1016/S0165-2478(01)00263-2 10.1016/j.vaccine.2008.03.066 10.4049/jimmunol.165.9.5170 10.3109/00365548.2011.653581 10.1038/ni.2035 10.1111/imr.12083 10.1097/QAD.0b013e32833e502b 10.1016/S1473-3099(13)70343-8 10.1016/j.vaccine.2013.07.037 10.1038/nature05115 10.1097/QAD.0b013e328353bcaf 10.4161/hv.19555 10.1016/j.vaccine.2011.11.003 10.1038/mi.2013.15 10.1089/088922202320935438 10.1084/jem.20041270 10.1016/j.immuni.2012.01.014 10.1038/nm1520 10.1111/j.1365-3083.2006.01730.x 10.1371/journal.pone.0009852 10.1111/imr.12069 10.1111/j.1600-065X.2006.00485.x 10.1097/00126334-200008010-00001 10.1371/journal.pone.0085604 10.1371/journal.pone.0070527 10.1016/S0140-6736(13)61809-7 10.4049/jimmunol.0803771 10.1038/nm1213 10.1097/01.aids.0000163932.76531.c6 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2014 Public Library of Science 2014 Brekke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. info:eu-repo/semantics/openAccess 2014 Brekke et al 2014 Brekke et al |
| Copyright_xml | – notice: COPYRIGHT 2014 Public Library of Science – notice: 2014 Brekke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: info:eu-repo/semantics/openAccess – notice: 2014 Brekke et al 2014 Brekke et al |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PIMPY PQEST PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 3HK 5PM DOA |
| DOI | 10.1371/journal.pone.0112556 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts ProQuest Nursing and Allied Health Journals Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (ProQuest) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Database (1962 - current) Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central Technology Collection ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) ProQuest Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic NORA - Norwegian Open Research Archives PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Biological Science Collection ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic Technology Collection Technology Research Database Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Public Health |
| DocumentTitleAlternate | Intranasal Therapeutic HIV Vaccine |
| EISSN | 1932-6203 |
| Editor | Goepfert, Paul A. |
| Editor_xml | – sequence: 1 givenname: Paul A. surname: Goepfert fullname: Goepfert, Paul A. |
| EndPage | e112556 |
| ExternalDocumentID | 1979936919 oai_doaj_org_article_18609084a09d4221b8537d67e7bc20ac 10852_42018 A418529607 10_1371_journal_pone_0112556 25398137 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Norway |
| GeographicLocations_xml | – name: Norway |
| GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BBORY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CGR CS3 CUY CVF D1I D1J D1K DIK DU5 E3Z EAP EAS EBD ECM EIF EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ NPM O5R O5S OK1 P2P P62 PATMY PDBOC PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RIG RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM AAYXX CITATION 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PQEST PQUKI PRINS RC3 7X8 3HK AAPBV ABPTK AFPKN N95 5PM - 02 ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c617t-b5aeb42d12c2b135ab992a54fda4586aa5843da877e97fd1c9bdca6addadc6e03 |
| IEDL.DBID | RPM |
| ISSN | 1932-6203 |
| IngestDate | Thu Nov 25 14:37:23 EST 2021 Tue Oct 22 15:16:09 EDT 2024 Tue Sep 17 20:48:02 EDT 2024 Sat Apr 29 05:43:15 EDT 2023 Fri Oct 25 06:43:16 EDT 2024 Thu Oct 10 16:12:54 EDT 2024 Tue Nov 19 20:40:33 EST 2024 Tue Nov 12 23:19:58 EST 2024 Fri Nov 22 00:43:52 EST 2024 Tue Oct 15 23:48:24 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c617t-b5aeb42d12c2b135ab992a54fda4586aa5843da877e97fd1c9bdca6addadc6e03 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 Conceived and designed the experiments: DK MS BS. Performed the experiments: KB AL IH. Analyzed the data: KB DK CH. Contributed reagents/materials/analysis tools: BS MS. Wrote the paper: KB AL CH BS MS DK. Competing Interests: This was an investigator-driven study, funded by the Research Council of Norway, where Vacc-4x was provided by Bionor Pharma. Maja Sommerfelt is currently employed as Chief Scientific Officer at Bionor Pharma and has shares in the company. Birger Sørensen is founder and former employee of Bionor and owns shares in the company. Maja Sommerfelt and Birger Sørensen confirm that this does not alter their adherence to PLOS ONE policies on sharing data and materials. |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232368/ |
| PMID | 25398137 |
| PQID | 1979936919 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1979936919 doaj_primary_oai_doaj_org_article_18609084a09d4221b8537d67e7bc20ac pubmedcentral_primary_oai_pubmedcentral_nih_gov_4232368 cristin_nora_10852_42018 proquest_miscellaneous_1628879731 proquest_journals_1979936919 gale_infotracmisc_A418529607 gale_infotracacademiconefile_A418529607 crossref_primary_10_1371_journal_pone_0112556 pubmed_primary_25398137 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-11-14 |
| PublicationDateYYYYMMDD | 2014-11-14 |
| PublicationDate_xml | – month: 11 year: 2014 text: 2014-11-14 day: 14 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2014 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | 15381726 - J Exp Med. 2004 Sep 20;200(6):701-12 24525316 - Lancet Infect Dis. 2014 Apr;14(4):291-300 20935558 - AIDS. 2010 Nov 13;24(17):2609-18 11015145 - J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):297-309 20583275 - Cytometry A. 2010 Jul;77(7):614-22 22406268 - Immunity. 2012 Mar 23;36(3):491-501 19093777 - Expert Rev Vaccines. 2009 Jan;8(1):103-12 15812489 - Nat Med. 2005 Apr;11(4 Suppl):S45-53 11595287 - Immunol Lett. 2001 Nov 1;79(1-2):29-36 22634436 - Hum Vaccin Immunother. 2012 May;8(5):569-81 22085556 - Vaccine. 2012 Jan 5;30(2):142-54 15802974 - AIDS. 2005 Mar 24;19(6):563-7 23906886 - Vaccine. 2013 Sep 23;31(41):4611-8 24152939 - Lancet. 2013 Nov 2;382(9903):1525-33 15585085 - AIDS Res Hum Retroviruses. 2004 Sep;20(9):972-88 17853861 - Nat Protoc. 2007;2(9):2057-67 21315623 - Immunity. 2011 Feb 25;34(2):269-80 23772621 - Immunol Rev. 2013 Jul;254(1):190-206 22441256 - AIDS. 2012 Jun 19;26(10):1281-92 21739672 - Nat Immunol. 2011 Jun;12(6):492-9 19414738 - J Immunol. 2009 May 15;182(10):5891-7 12487807 - AIDS Res Hum Retroviruses. 2002 Dec 10;18(18):1357-65 24690149 - Vaccine. 2014 May 30;32(26):3307-15 16921384 - Nature. 2006 Sep 21;443(7109):350-4 22339485 - Scand J Infect Dis. 2012 Aug;44(8):566-72 23541541 - Lancet. 2013 Jun 15;381(9883):2109-17 20352042 - PLoS One. 2010;5(3):e9852 23549448 - Mucosal Immunol. 2013 Jul;6(4):657-65 23950951 - PLoS One. 2013;8(8):e70527 18450334 - Vaccine. 2008 Sep 19;26(40):5075-8 23772631 - Immunol Rev. 2013 Jul;254(1):355-71 16499576 - Scand J Immunol. 2006 Mar;63(3):223-31 1441735 - Vaccine. 1992;10(11):802-5 17367342 - Immunol Rev. 2007 Apr;216:164-75 23437055 - PLoS One. 2013;8(2):e55438 17173051 - Nat Med. 2007 Jan;13(1):46-53 24416431 - PLoS One. 2014;9(1):e85604 11046049 - J Immunol. 2000 Nov 1;165(9):5170-6 15353973 - AIDS. 2004 Sep 24;18(14):1875-83 22528766 - Curr HIV/AIDS Rep. 2012 Jun;9(2):139-47 P Kiepiela (ref9) 2007; 13 A Lind (ref26) 2014; 9 SG Deeks (ref3) 2013; 382 H Bakke (ref27) 2006; 63 ref1 D Kvale (ref38) 2005; 19 ref17 A Lind (ref12) 2012; 44 C Katlama (ref8) 2013; 381 J Holmgren (ref20) 2005; 11 BD Forrest (ref29) 1992; 10 A Lind (ref25) 2013; 31 J Mestecky (ref35) 2004; 20 EJ Wherry (ref23) 2011; 12 G Leroux-Roels (ref30) 2013; 8 RB Pollard (ref13) 2014; 14 AB McDermott (ref5) 2012; 26 V Pavot (ref18) 2012; 30 M Lichterfeld (ref40) 2004; 200 AM Kran (ref14) 2010; 24 JM Brenchley (ref32) 2013; 6 F Garcia (ref4) 2012; 8 PW Hunt (ref2) 2012; 9 M Bomsel (ref31) 2011; 34 JF Mann (ref21) 2009; 8 L Shan (ref6) 2012; 36 KR Demers (ref36) 2013; 254 G Carcelain (ref7) 2013; 254 AK Maltais (ref16) 2014; 32 K Broliden (ref34) 2001; 79 T Falkeborn (ref15) 2013; 8 PK Chattopadhyay (ref39) 2010; 77 MP Davenport (ref37) 2007; 216 CL Day (ref41) 2006; 443 DE Kaufmann (ref22) 2009; 182 ED Hawkins (ref42) 2007; 2 PA Kozlowski (ref28) 2000; 24 C Devito (ref33) 2000; 165 B Asjo (ref10) 2002; 18 AM Kran (ref11) 2004; 18 A Brave (ref19) 2008; 26 BJ Macatangay (ref24) 2010; 5 |
| References_xml | – ident: ref1 – volume: 34 start-page: 269 year: 2011 ident: ref31 article-title: Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges publication-title: Immunity doi: 10.1016/j.immuni.2011.01.015 contributor: fullname: M Bomsel – volume: 8 start-page: e55438 year: 2013 ident: ref30 article-title: Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes publication-title: PLoS One doi: 10.1371/journal.pone.0055438 contributor: fullname: G Leroux-Roels – volume: 20 start-page: 972 year: 2004 ident: ref35 article-title: Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2004.20.972 contributor: fullname: J Mestecky – volume: 2 start-page: 2057 year: 2007 ident: ref42 article-title: Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data publication-title: Nat Protoc doi: 10.1038/nprot.2007.297 contributor: fullname: ED Hawkins – volume: 381 start-page: 2109 year: 2013 ident: ref8 article-title: Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs publication-title: Lancet doi: 10.1016/S0140-6736(13)60104-X contributor: fullname: C Katlama – volume: 8 start-page: 103 year: 2009 ident: ref21 article-title: Delivery systems: a vaccine strategy for overcoming mucosal tolerance? publication-title: Expert Rev Vaccines doi: 10.1586/14760584.8.1.103 contributor: fullname: JF Mann – volume: 10 start-page: 802 year: 1992 ident: ref29 article-title: Effects of sample processing on the measurement of specific intestinal IgA immune responses publication-title: Vaccine doi: 10.1016/0264-410X(92)90517-N contributor: fullname: BD Forrest – volume: 77 start-page: 614 year: 2010 ident: ref39 article-title: Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease publication-title: Cytometry A doi: 10.1002/cyto.a.20905 contributor: fullname: PK Chattopadhyay – volume: 18 start-page: 1875 year: 2004 ident: ref11 article-title: HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x) publication-title: AIDS doi: 10.1097/00002030-200409240-00003 contributor: fullname: AM Kran – volume: 32 start-page: 3307 year: 2014 ident: ref16 article-title: Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets publication-title: Vaccine doi: 10.1016/j.vaccine.2014.03.061 contributor: fullname: AK Maltais – volume: 9 start-page: 139 year: 2012 ident: ref2 article-title: HIV and inflammation: mechanisms and consequences publication-title: Curr HIV/AIDS Rep doi: 10.1007/s11904-012-0118-8 contributor: fullname: PW Hunt – volume: 79 start-page: 29 year: 2001 ident: ref34 article-title: Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers publication-title: Immunol Lett doi: 10.1016/S0165-2478(01)00263-2 contributor: fullname: K Broliden – volume: 26 start-page: 5075 year: 2008 ident: ref19 article-title: Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses publication-title: Vaccine doi: 10.1016/j.vaccine.2008.03.066 contributor: fullname: A Brave – volume: 165 start-page: 5170 year: 2000 ident: ref33 article-title: Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells publication-title: J Immunol doi: 10.4049/jimmunol.165.9.5170 contributor: fullname: C Devito – volume: 44 start-page: 566 year: 2012 ident: ref12 article-title: Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4+ and CD8+T cell responses lasting more than seven years publication-title: Scand J Infect Dis doi: 10.3109/00365548.2011.653581 contributor: fullname: A Lind – volume: 12 start-page: 492 year: 2011 ident: ref23 article-title: T cell exhaustion publication-title: Nat Immunol doi: 10.1038/ni.2035 contributor: fullname: EJ Wherry – volume: 254 start-page: 355 year: 2013 ident: ref7 article-title: Immune interventions in HIV infection publication-title: Immunol Rev doi: 10.1111/imr.12083 contributor: fullname: G Carcelain – ident: ref17 – volume: 24 start-page: 2609 year: 2010 ident: ref14 article-title: Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides publication-title: AIDS doi: 10.1097/QAD.0b013e32833e502b contributor: fullname: AM Kran – volume: 14 start-page: 291 year: 2014 ident: ref13 article-title: Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(13)70343-8 contributor: fullname: RB Pollard – volume: 31 start-page: 4611 year: 2013 ident: ref25 article-title: Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms publication-title: Vaccine doi: 10.1016/j.vaccine.2013.07.037 contributor: fullname: A Lind – volume: 443 start-page: 350 year: 2006 ident: ref41 article-title: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression publication-title: Nature doi: 10.1038/nature05115 contributor: fullname: CL Day – volume: 26 start-page: 1281 year: 2012 ident: ref5 article-title: CD8(+) T cells in preventing HIV infection and disease publication-title: AIDS doi: 10.1097/QAD.0b013e328353bcaf contributor: fullname: AB McDermott – volume: 8 start-page: 569 year: 2012 ident: ref4 article-title: Therapeutic vaccines against HIV infection publication-title: Hum Vaccin Immunother doi: 10.4161/hv.19555 contributor: fullname: F Garcia – volume: 30 start-page: 142 year: 2012 ident: ref18 article-title: New insights in mucosal vaccine development publication-title: Vaccine doi: 10.1016/j.vaccine.2011.11.003 contributor: fullname: V Pavot – volume: 6 start-page: 657 year: 2013 ident: ref32 article-title: Mucosal immunity in human and simian immunodeficiency lentivirus infections publication-title: Mucosal Immunol doi: 10.1038/mi.2013.15 contributor: fullname: JM Brenchley – volume: 18 start-page: 1357 year: 2002 ident: ref10 article-title: Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy publication-title: AIDS Res Hum Retroviruses doi: 10.1089/088922202320935438 contributor: fullname: B Asjo – volume: 200 start-page: 701 year: 2004 ident: ref40 article-title: Loss of HIV-1-specific CD8+T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+T cells publication-title: J Exp Med doi: 10.1084/jem.20041270 contributor: fullname: M Lichterfeld – volume: 36 start-page: 491 year: 2012 ident: ref6 article-title: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation publication-title: Immunity doi: 10.1016/j.immuni.2012.01.014 contributor: fullname: L Shan – volume: 13 start-page: 46 year: 2007 ident: ref9 article-title: CD8+T-cell responses to different HIV proteins have discordant associations with viral load publication-title: Nat Med doi: 10.1038/nm1520 contributor: fullname: P Kiepiela – volume: 63 start-page: 223 year: 2006 ident: ref27 article-title: Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity publication-title: Scand J Immunol doi: 10.1111/j.1365-3083.2006.01730.x contributor: fullname: H Bakke – volume: 5 start-page: e9852 year: 2010 ident: ref24 article-title: Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART publication-title: PLoS One doi: 10.1371/journal.pone.0009852 contributor: fullname: BJ Macatangay – volume: 254 start-page: 190 year: 2013 ident: ref36 article-title: CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis publication-title: Immunol Rev doi: 10.1111/imr.12069 contributor: fullname: KR Demers – volume: 216 start-page: 164 year: 2007 ident: ref37 article-title: Understanding the mechanisms and limitations of immune control of HIV publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2006.00485.x contributor: fullname: MP Davenport – volume: 24 start-page: 297 year: 2000 ident: ref28 article-title: Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200008010-00001 contributor: fullname: PA Kozlowski – volume: 9 start-page: e85604 year: 2014 ident: ref26 article-title: A Parameter for IL-10 and TGF-ss Mediated Regulation of HIV-1 Specific T Cell Activation Provides Novel Information and Relates to Progression Markers publication-title: PLoS One doi: 10.1371/journal.pone.0085604 contributor: fullname: A Lind – volume: 8 start-page: e70527 year: 2013 ident: ref15 article-title: Endocine, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination publication-title: PLoS One doi: 10.1371/journal.pone.0070527 contributor: fullname: T Falkeborn – volume: 382 start-page: 1525 year: 2013 ident: ref3 article-title: The end of AIDS: HIV infection as a chronic disease publication-title: Lancet doi: 10.1016/S0140-6736(13)61809-7 contributor: fullname: SG Deeks – volume: 182 start-page: 5891 year: 2009 ident: ref22 article-title: PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention publication-title: J Immunol doi: 10.4049/jimmunol.0803771 contributor: fullname: DE Kaufmann – volume: 11 start-page: S45 year: 2005 ident: ref20 article-title: Mucosal immunity and vaccines publication-title: Nat Med doi: 10.1038/nm1213 contributor: fullname: J Holmgren – volume: 19 start-page: 563 year: 2005 ident: ref38 article-title: Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia publication-title: AIDS doi: 10.1097/01.aids.0000163932.76531.c6 contributor: fullname: D Kvale |
| SSID | ssj0053866 |
| Score | 2.3037899 |
| Snippet | Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized... Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this... BACKGROUNDVacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized... Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this... |
| SourceID | plos doaj pubmedcentral cristin proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e112556 |
| SubjectTerms | Acquired immune deficiency syndrome Administration, Intranasal AIDS AIDS vaccines AIDS Vaccines - administration & dosage AIDS Vaccines - pharmacology Analysis Antibodies Antigens Biology and Life Sciences Bone morphogenetic proteins CD4 antigen CD8 antigen Control Cytokines Dose-Response Relationship, Immunologic Drug resistance Enzyme-Linked Immunosorbent Assay Health aspects HIV Hospitals Human immunodeficiency virus Humans Immune response Immunity Immunity, Mucosal - drug effects Immunity, Mucosal - immunology Immunogenicity Immunoglobulin A Immunoglobulin G Immunoglobulins Immunoregulation In vivo methods and tests Infections Infectious diseases Interleukin 10 Interleukin-10 - immunology Intranasal administration Lactoferrin Lymphocytes Lymphocytes T Mucosal immunity Peptides Public health Randomization Rectum Secretions Skin Skin tests Statistics, Nonparametric T cell receptors T cells Transforming Growth Factor beta - immunology Transforming growth factors Vaccination Vaccines Viral Load - drug effects |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggymtDCzISEu0hbR6OHR8Lotpy4ESr3qzxI2KlNlk1uwjxY_itzCTe1QZV4sItil-Jv5nxWB5_w9h7XLXAVRrSymrcoDhtU2gqVDxc26GC4Es3sH1-lYsr8eWmutlL9UUxYSM98DhxZ3ktM53VAjLtRVHkFtcX5aUKyroiAzdY32y3mRptMGqxlPGiXKnys4jL6aprwylKNPFuocPrBj1qJ0vSwNy_s8-z1W3XP-R8_h1DubcoXTxlT6I3yc_Hvzhgj0L7jB1Efe35cSSVPnnOfl9SBy30WB0mhLm8azjwvXtYfHF5zX-AoyN3fnyND6n4ecJx876hTn3Xh3SbO3fNRypobAWt53cU_44jLOnWSeD3YwAuNlq2OAaO77u75a_geYyQv8XHIW_IC3Z18fnbp0UaczOkDn2edWoRRysKnxeusHlZgdUawRWNB1HVEgAdm9JDrVTQqvE5CoF3INGagncyZOVLNmsRjTnjoinBoR-h0OyKJlMWPc4ik1bUja58VidsHoEyLaoFUZpWhRHouWBRukXOrEZ2DjMc0Snc1YwQGMLcRMwT9pHg3dUlbu3hBUqciRJn_iVxCftAwmHIAiBSDuJFBhyHuLTMOfEBFbgzVAk7mtREzXWT4jmJ1_ZLe5PTGWspda6x5VbkHi5-tyumTilQrg3dButQ-mhF-cgS9mqU0N3fFlWpa5ybhKmJ7E6mY1rSLr8PlON0nF_K-vX_mL9D9hixE3ShMxdHbLa-34Q36Nmt7dtBif8AbatNWQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegvCAhxMZHMwYyEhLbQ7bEcez4CY2N0iLBw9RNe7Mc24FKI-mWTkL8Mfyt3CVuR9DEW1R_pbkPn313vyPkLexaxubKxHmp4IBiVRmbKgfBg73d5Ma7zHZon1_F9Ix_vsgvwoVbG8Iq1zqxU9SusXhHfpii_ykTKlXvl1cxVo1C72oooXGfPEiZlFi6oZh8WmtikGUhQrpcJtPDQJ2DZVP7A-BrRN8Cs9d20lQPNqYOv3-jpUfLy6a9ywT9N5Lyr61p8oQ8DjYlPeqZYIvc8_U2edRfyNE-z2ibbAUpbulegJref0p-z3DC2rQ4fACjS5uKGjq_zc6i09k5PTcWHfF0Dx9i_nOfYukPnPSkaX18EirqrmgPhA6jTO3oF4yKhxVmmIvi6WkflguDFjWscQpdmh-LX97R4z5u_hIe5ygYz8jZ5OP8eBqHig2xBUtoFZdA3ZIzlzLLyjTLTakUkJxXzvC8EMaAuZM5U0jplaxcCqzhrBGgY42zwifZczKqgTpjQnmVGQvWhQRlzKtElmCHskSUvKhU7pIiIuNAOF2DsCDQac40B3sGmuI1JfWyx-zQneNOwlmnJ4lGHtCBByLyAcm96YuI290PzfU3HQRYp4VIVFJwkyjHGUtLsHOkE9LL0rLE2Ii8Q2bRqBeAUtaE9AZYBxG29BGiBDE4L8qI7A56gjzbQfMY2W39pq2-5XwYuWbBu5vfbJpxUgyfq31zA32wqLTEKmURedFz7ObfsjxTBXybiMgBLw8-x7ClXnzvgMjRyZ-JYuf_r_WSPASqcEzgTPkuGa2ub_wrsORW5etOXP8A83NJbA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbKIiQuiPLaQEFGQqI9ZJWHY8cHhEpLtYtUDtVu1VvkV8pKS7JstlLhx_BbmckLgpYLt2g9Y2fzzdhjjf0NIW9g1VImkcpPtIQNipHaV3kCjgdru0qUs7Gp2T4_8-mCfbpKrvZIV7O1_YDVzq0d1pNabFaT22_f34PDv6urNoiwU5qsy8JNwF6RVesOuRuxuA6ZzlmfVwDv5ry9QPcvTaQHTmKZhlga_Z6pXa0YrFo1uX8_hY_Wq7LaFZ_-fczyj3Xr7CF50Aac9LixkH2y54pHZL916YoetrzTR4_Jzxl2UKgKxQecurTMqaLz31e16HR2SS-Vwaw8PcQHn90eUawDgp2elpXzT9vyulvasKKDliosPccj8jDCDC-mOHrRnNEFpWUBY1yASPl1-cNZetIcol_B4xy95AlZnH2cn0z9tnyDbyAs2voaoNYssmFkIh3GidJSAv4st4olKVcKYp_YqlQIJ0VuQ7ATaxSHCVdZw10QPyWjAoAZE8ryWBkINQTMzCwPhIagNAq4ZmkuExukHhm3QGUFeA6yniZRxiC4gSa_Qy5bNwQeWZ3FE7DxaSDIEP6shd8jHxDeXhbpt-sfys111npzFqY8kEHKVCAti6JQQ9AjLBdOaBMFynjkLRpHhmYLSBnV3nWAcZBuKztGyqAINo_CIwcDSXBuM2geo3l1b1plIaZhYy5DCZqdye1uft03Y6d4lq5w5Q3IYIVpgSXLPPKssdD-33aW7xExsN3B5xi2FMsvNSs5Zvxjnj7_b80X5D4AxvCiZ8gOyGi7uXEvIeLb6le1E_8CDdZXdA priority: 102 providerName: Scholars Portal |
| Title | Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25398137 https://www.proquest.com/docview/1979936919 https://search.proquest.com/docview/1628879731 http://hdl.handle.net/10852/42018 https://pubmed.ncbi.nlm.nih.gov/PMC4232368 https://doaj.org/article/18609084a09d4221b8537d67e7bc20ac http://dx.doi.org/10.1371/journal.pone.0112556 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF4Sl0IvpenLalOzhUKTg2w9VlrtMXHs2gWHYJyQm9iHlBpsycQOlB76U_pbOyOt3Krk1MsivC_Z38zurHfmG0I-wa4ldSSkGykBBxQtlCvzCBQP9nYZycyEumL7vIwn1-zrbXR7QKImFqZy2tdq2S9W636x_Fb5Vm7WetD4iQ2uZkO8XAzjZHBIDnmQNEf0evkFBY5jGyMXcn9gIelvyiLrgzAj5RYyAEehSHzMfv5UV9pUtDamir9_v0p3Nqty-5gJ-q8n5V9b0_gFeW5tSnpWv_sROciKl-TIau2Wnlhq6dNX5NcUByjkFpu3aHNpmVNJF3-isehkekNvpMaLd3qCDy77fkox1QcOelFuM_fCZtDd0Zr4HHrJwtAZesHDDFOMPcnovHbDhU7LAuaYQ5NyvfyRGTqs_eRX8LhARXhNrsejxXDi2gwNrgbLZ-cqQFOxwPiBDpQfRlIJARCz3EgWJbGUYN6ERiacZ4LnxgdRMFrGsKZKo-PMC9-QTgHAdAlleSg1WBMcFl-We1yB3Rl4sWJJLiLjJQ7pWqDSApQDiU2jIGVgv0CV2yCXbmqOjrS6qONwtqkhSBH-1MLvkHOEd98WGbarD8r7u9TKWeonsSe8hElPGBYEvgK7hpuYZ1zpwJPaIZ9ROFJcBwApLW04A8yDjFrpGbICBXA-5A45brUE_dWt6i6KV_Om29THm9YwFr6Ano3IPV79cV-Ng6K7XJGVD9AGk0hzzErmkLe1hO6_bSP5DuEt2W39HO0a0MOKeNzq3bv_7vmePAPAGMZy-uyYdHb3D9kHMOp2qgeqfMuhTIY-luMvPfLkfHR5Ne9Vf5NAOWMJlj9HvUrhfwPdq1R9 |
| link.rule.ids | 230,315,728,781,785,865,886,2103,2222,12061,12228,12770,21393,24323,27929,27930,31724,31725,33271,33272,33378,33379,33749,33750,43315,43584,43605,43810,53796,53798,73750,74019,74040,74307 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zb9QwELZg-wASQrQcGyhgJCTah7Q5HDt-Qj21C-0KVduqb5aPBFYqydJsJcSP4bcyk3i3BFW8Resrmzk89sx8Q8h72LW0zaQOMyPhgGKlCXWZgeDB3q4zXbjUtmifEz46Z58us0t_4db4sMqlTmwVtast3pHvxuh_SrmM5cf5jxCrRqF31ZfQuE_WWqiqAVnbP5p8OVvqYpBmzn3CXCriXU-fnXldFTvA2Yi_BYavbeWp6m1NLYL_Sk8P5ld1c5cR-m8s5V-b0_ET8thblXSvY4N1cq-oNsij7kqOdplGG2Tdy3FDtzzY9PZT8nuME1a6weE9IF1al1TT6W1-Fh2NL-iFtuiKp1v4ELKf2xSLf-Ckh3VThIe-pu6CdlDoMEpXjp5iXDysMMZslIKedYG5MGhWwRpn0KX-PvtVOHrQRc5fweMUReMZOT8-mh6MQl-zIbRgCy1CA_Q1LHFxYhMTp5k2UgLRWek0y3KuNRg8qdO5EIUUpYuBOZzVHLSsdpYXUfqcDCqgzpBQVqbagn0hQB2zMhIGLNEk4oblpcxclAdk6AmnKhAXhDrNEsXAooGmcElJNe9QO1TruhNw2ulIopAHlOeBgOwjuVd9EXO7_aG-_qq8CKs455GMcqYj6ViSxAYsHeG4KISxSaRtQD4gsyjUDEApq32CA6yDGFtqD3GCEjgxioBs9nqCRNte8xDZbfmmjbrlfRi5ZMG7m9-tmnFSDKCrivoG-mBZaYF1ygLyouPY1b9NslTm8G0CInq83Psc_ZZq9q2FIkc3f8rzl_9_rbfkwWh6eqJOxpPPr8hDoBDDdM6YbZLB4vqmeA123cK88cL7BwlCTb0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3bbtNAEF1BKiEkhGiBxlBgkZBoH9z4svZ6n1DbNEq4RFWUVn1b7cWGSMUOdSohPoZvZcbepBhVvFnZix3PnNlZ78wZQt7BqqVMIpSfaAEbFCO0r4oEgAdru0pUbmPTsH1O0_E5-3iZXLr4p9qFVa5tYmOobWXwG_kgxPOnOBWhGBQuLOJsOPqw_OFjBSk8aXXlNO6TLVgVA9iIbR2fTs9ma7sMyE5TlzwX83DgZHW4rMr8ELQcubjACTYNtsrOMtWw-W9sdm95VdV3OaT_xlX-tVCNnpDHzsOkR61KbJN7eblDHrWf52ibdbRDth2ma7rviKcPnpLfE5ywVDUO75Dq0qqgis5vc7XoeHJBL5TBY3m6jxc--3lAsRAITjqs6twfuvq6K9rSosMoVVr6BWPk4Q4TzEzJ6awN0oVBixLuMYMu1ffFr9zSkzaK_gou5wiTZ-R8dDo_GfuufoNvwC9a-RpkrVlkw8hEOowTpYUABWCFVSzJUqXA-YmtyjjPBS9sCIpijUrB4ipr0jyIn5NeCdLpE8qKWBnwNTiYZlYEXINXGgWpZlkhEhtkHuk7wckSoIO0p0kkGXg30OSvJSmXLYOHbI7xOOx8WpFI1AHpdMAjxyjuTV_k325-qK6_SgdnGWZpIIKMqUBYFkWhBq-H25TnXJsoUMYj71FZJFoJkJRRLtkB7oN8W_IIOYMi2D1yj-x1egK6Tae5j-q2ftJa3uIARq5V8O7mt5tmnBSD6cq8uoE-WGKaY80yj-y2Grv5t1ESiwzejUd4R5c7r6PbUi6-NbTkeOQfp9mL_z_WG_IAcCs_T6afXpKHICCGmZ0h2yO91fVN_gpcvJV-7bD7B9MLUfM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intranasal+Administration+of+a+Therapeutic+HIV+Vaccine+%28Vacc-4x%29+Induces+Dose-Dependent+Systemic+and+Mucosal+Immune+Responses+in+a+Randomized+Controlled+Trial&rft.jtitle=PloS+one&rft.au=Brekke%2C+Kristin&rft.au=Lind%2C+Andreas&rft.au=Holm-Hansen%2C+Carol&rft.au=Haugen%2C+Inger+Lise&rft.date=2014-11-14&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=9&rft.issue=11&rft_id=info:doi/10.1371%2Fjournal.pone.0112556&rft_id=info%3Apmid%2F25398137&rft.externalDBID=PMC4232368 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |